Antiretroviral treatment of HIV infection: Swedish recommendations 2007

References

• Shafer RW, Smeaton LM, Robbins GK, De Gruttola V, Snyder SW, D'Aquila RT, et al. Comparison of 4-drug regimens and pairs of sequential 3-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349: 2304–15
   PubMed Web of Science ®Google Scholar
• Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA III, et al. Three- vs 4-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 2006; 296: 769–81
   PubMed Web of Science ®Google Scholar
• DeJesus E, Herrera G, Teofilo E, Gerstoft J, Buendia CB, Brand JD, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 2004; 39: 1038–46
   PubMed Web of Science ®Google Scholar
• Bartlett JA, Johnson J, Herrera G, Sosa N, Rodriguez A, Liao Q, et al. Long-term results of initial therapy with abacavir and lamivudine combined with efavirenz, amprenavir/ritonavir, or stavudine. J Acquir Immune Defic Syndr 2006; 43: 284–92
   PubMed Web of Science ®Google Scholar
• Eron J, Jr, Yeni P, Gathe J, Jr, Estrada V, DeJesus E, Staszewski S, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomized non-inferiority trial. Lancet 2006; 368: 476–82
   PubMed Web of Science ®Google Scholar
• Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 2006; 43: 99–102
   PubMed Web of Science ®Google Scholar
• Pozniak AL, Gallant JE, DeJesus E, Arribas JR, Gazzard B, Campo RE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virological, immunological, and morphological changes: a 96-week analysis. J Acquir Immune Defic Syndr 2006; 43: 535–40
   PubMed Web of Science ®Google Scholar
• Havlir DV, Tierney C, Friedland GH, Pollard RB, Smeaton L, Sommadossi JP, et al. In vivo antagonism with zidovudine plus stavudine combination therapy. J Infect Dis 2000; 182: 321–5
   PubMed Web of Science ®Google Scholar
• Gallant JE, Rodriguez AE, Weinberg WG, Young B, Berger DS, Lim ML, et al. Early virological non-response to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis 2005; 192: 1921–30
   PubMed Web of Science ®Google Scholar
• Leon A, Mallolas J, Martinez E, De Lazzari E, Pumarola T, Larrousse M, et al. High rate of virological failure in maintenance antiretroviral therapy with didanosine and tenofovir. Aids 2005; 19: 1695–7
   PubMed Web of Science ®Google Scholar
• Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, et al. Comparison of sequential 3-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349: 2293–303
   PubMed Web of Science ®Google Scholar
• Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr 2004; 35: 538–9
   PubMed Web of Science ®Google Scholar
• Stocrin, SPC, Merck, Sharpe and Dohme. 2007. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Stocrin/H-250-PI-en.pdf.
   Google Scholar
• Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346: 2039–46
   PubMed Web of Science ®Google Scholar
• Kempf DJ, King MS, Bernstein B, Cernohous P, Bauer E, Moseley J, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004; 189: 51–60
   PubMed Web of Science ®Google Scholar
• Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. Aids 2005; 19: 685–94
   PubMed Web of Science ®Google Scholar
• Kuritzkes DR. Preventing and managing resistance in the clinical setting. J Acquir Immune Defic Syndr 2003; 34(Suppl 2)S103–10
   PubMed Web of Science ®Google Scholar
• Beerenwinkel N, Daumer M, Sing T, Rahnenfuhrer J, Lengauer T, Selbig J, et al. Estimating HIV evolutionary pathways and the genetic barrier to drug resistance. J Infect Dis 2005; 191: 1953–60
   PubMed Web of Science ®Google Scholar
• Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003; 37: 113–28
   PubMed Web of Science ®Google Scholar
• Vandamme AM, Sonnerborg A, Ait-Khaled M, Albert J, Asjo B, Bacheler L, et al. Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther 2004; 9: 829–48
   PubMed Web of Science ®Google Scholar
• Rizzardi GP, De Boer RJ, Hoover S, Tambussi G, Chapuis A, Halkic N, et al. Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA. J Clin Invest 2000; 105: 777–82
   PubMed Web of Science ®Google Scholar
• Furrer H, Egger M, Opravil M, Bernasconi E, Hirschel B, Battegay M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med 1999; 340: 1301–6
   PubMed Web of Science ®Google Scholar
• El-Sadr WM, Burman WJ, Grant LB, Matts JP, Hafner R, Crane L, et al. Discontinuation of prophylaxis for Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 2000; 342: 1085–92
   PubMed Web of Science ®Google Scholar
• Jouan M, Saves M, Tubiana R, Carcelain G, Cassoux N, Aubron-Olivier C, et al. Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy. Aids 2001; 15: 23–31
   PubMed Web of Science ®Google Scholar
• Mussini C, Pezzotti P, Govoni A, Borghi V, Antinori A, d'Arminio Monforte A, et al. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type 1-infected patients: the changes in opportunistic prophylaxis study. J Infect Dis 2000; 181: 1635–42
   PubMed Web of Science ®Google Scholar
• El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283–96
   PubMed Web of Science ®Google Scholar
• Nettles RE, Kieffer TL, Kwon P, Monie D, Han Y, Parsons T, et al. Intermittent HIV-1 viraemia (blips) and drug resistance in patients receiving HAART. JAMA 2005; 293: 817–29
   PubMed Web of Science ®Google Scholar
• Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995; 171: 1411–9
   PubMed Web of Science ®Google Scholar
• Richman DD, Havlir D, Corbeil J, Looney D, Ignacio C, Spector SA, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994; 68: 1660–6
   PubMed Web of Science ®Google Scholar
• Deeks SG, Hoh R, Neilands TB, Liegler T, Aweeka F, Petropoulos CJ, et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis 2005; 192: 1537–44
   PubMed Web of Science ®Google Scholar
• Castagna A, Danise A, Menzo S, Galli L, Gianotti N, Carini E, et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). Aids 2006; 20: 795–803
   PubMed Web of Science ®Google Scholar
• Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimized background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from 2 randomized open-label trials. Lancet 2006; 368: 466–75
   PubMed Web of Science ®Google Scholar
• Youle M, Staszweski S, Clotet B, Arribas JR, Blaxhult A, Carosi G, et al. Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations. HIV Clin Trials 2006; 7: 86–96
   PubMed Web of Science ®Google Scholar
• Nelson M, Arasteh K, Clotet B, Cooper DA, Henry K, Katlama C, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005; 40: 404–12
   PubMed Web of Science ®Google Scholar
• Naver L, Lindgren S, Belfrage E, Gyllensten K, Lidman K, Gisslen M, et al. Children born to HIV-1-infected women in Sweden in 1982–2003: trends in epidemiology and vertical transmission. J Acquir Immune Defic Syndr 2006; 42: 484–9
   PubMed Web of Science ®Google Scholar
• McIntosh K, Shevitz A, Zaknun D, Kornegay J, Chatis P, Karthas N, et al. Age- and time-related changes in extracellular viral load in children vertically infected by human immunodeficiency virus. Pediatr Infect Dis J 1996; 15: 1087–91
   PubMed Web of Science ®Google Scholar
• Age-related standards for T-lymphocyte subsets based on uninfected children born to human immunodeficiency virus 1-infected women. The European Collaborative Study. Pediatr Infect Dis J 1992;11:1018–26.
   PubMed Web of Science ®Google Scholar
• Dunn D. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet 2003; 362: 1605–11
   PubMed Web of Science ®Google Scholar
• Sharland M, Blanche S, Castelli G, Ramos J, Gibb DM. PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med 2004; 5(Suppl 2)61–86
   PubMed Web of Science ®Google Scholar
• McComsey GA, Leonard E. Metabolic complications of HIV therapy in children. Aids 2004; 18: 1753–68
   PubMed Web of Science ®Google Scholar
• Smith DE, Walker BD, Cooper DA, Rosenberg ES, Kaldor JM. Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence?. Aids 2004; 18: 709–18
   PubMed Web of Science ®Google Scholar
• Goh LE, Perrin L, Hoen B, Cooper D, Phillips A, Janossy G, et al. Study protocol for the evaluation of the potential for durable viral suppression after quadruple HAART with or without HIV vaccination: the QUEST study. HIV Clin Trials 2001; 2: 438–44
   PubMedGoogle Scholar
• Nilsson J, Kinloch-de-Loes S, Granath A, Sonnerborg A, Goh LE, Andersson J. Early immune activation in gut-associated and peripheral lymphoid tissue during acute HIV infection. Aids 2007; 21: 565–74
   PubMed Web of Science ®Google Scholar
• Apetrei C, Tamalet C, Edlinger C, Damond F, Descamps D, Saimot AG, et al. Delayed HIV-1 seroconversion after antiretroviral therapy. Aids 1998; 12: 1935–6
   PubMed Web of Science ®Google Scholar
• Telzir, SPC. Glaxo. 2007. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/telzir/H-534-PI-en.pdf.
   Google Scholar
• Sulkowski MS. Treatment algorithm for the management of hepatitis C in HIV-coinfected persons. J Hepatol 2006; 44(Suppl 1)S49–55
   PubMed Web of Science ®Google Scholar
• Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palu G, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV coinfected patients. J Hepatol 2005; 42: 615–24
   PubMed Web of Science ®Google Scholar
• Rey D, Krantz V, Partisani M, Schmitt MP, Meyer P, Libbrecht E, et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine 2000; 18: 1161–5
   PubMed Web of Science ®Google Scholar
• Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000; 12: 255–66
   PubMed Web of Science ®Google Scholar
• Hecht FM. Measuring HIV treatment adherence in clinical practice. AIDS Clin Care 1998; 10: 57–9
   PubMedGoogle Scholar
• Mellors JW, Rinaldo CR, Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272: 1167–70
   PubMed Web of Science ®Google Scholar
• Katzenstein TL, Ullum H, Roge BT, Wandall J, Dickmeiss E, Barrington T, et al. Virological and immunological profiles among patients with undetectable viral load followed prospectively for 24 months. HIV Med 2003; 4: 53–61
   PubMedGoogle Scholar
• Devereux HL, Youle M, Johnson MA, Loveday C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. Aids 1999; 13: F123–7
   PubMed Web of Science ®Google Scholar
• Izopet J, Massip P, Souyris C, Sandres K, Puissant B, Obadia M, et al. Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen. Aids 2000; 14: 2247–55
   PubMed Web of Science ®Google Scholar
• Verhofstede C, Wanzeele FV, van der Gucht B, De Cabooter N, Plum J. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. Aids 1999; 13: 2541–6
   PubMed Web of Science ®Google Scholar
• Miller V, Sabin C, Hertogs K, Bloor S, Martinez-Picado J, D'Aquila R, et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. Aids 2000; 14: 2857–67
   PubMed Web of Science ®Google Scholar
• Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, et al. Virological and immunological consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viraemia. N Engl J Med 2001; 344: 472–80
   PubMed Web of Science ®Google Scholar
• Khoo SH, Lloyd J, Dalton M, Bonington A, Hart E, Gibbons S, et al. Pharmacological optimization of protease inhibitors and non-nucleoside reverse transcriptase inhibitors (POPIN): a randomized controlled trial of therapeutic drug monitoring and adherence support. J Acquir Immune Defic Syndr 2006; 41: 461–7
   PubMed Web of Science ®Google Scholar
• Viread, SPC. Gilead Sciences. 2007. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/viread/H-419-PI-en.pdf
   Google Scholar
• Moreno A, Quereda C, Moreno L, Perez-Elias MJ, Muriel A, Casado JL, et al. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. Antivir Ther 2004; 9: 133–8
   PubMed Web of Science ®Google Scholar
• Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat 2006; 13: 683–9
   PubMed Web of Science ®Google Scholar
• Rendon AL, Nunez M, Romero M, Barreiro P, Martin-Carbonero L, Garcia-Samaniego J, et al. Early monitoring of ribavirin plasma concentrations may predict anaemia and early virological response in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2005; 39: 401–5
   PubMed Web of Science ®Google Scholar
• Aptivus, SPC. Boehringer lngelheim. 2007. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/aptivus/H-631-PI-en.pdf
   Google Scholar
• Reyataz, SPC. Bristol Myers Squibb. 2007. http://www.emea.europa.eu/humandocs/PDFs/EPAR/reyataz/H-494-PI-en.pdf
   Google Scholar
• Ouellet D, Hsu A, Qian J, Locke CS, Eason CJ, Cavanaugh JH, et al. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol 1998; 46: 111–6
   PubMed Web of Science ®Google Scholar
• Videx EC SPC. Bristol Myers Squibb. 2007. Available at: http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=3596#PRODUCTINFO.
   Google Scholar
• Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John's wort. Lancet 2000; 355: 547–8
   PubMed Web of Science ®Google Scholar
• van der Valk M, Casula M, Weverlingz GJ, van Kuijk K, van Eck-Smit B, Hulsebosch HJ, et al. Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy. Antivir Ther 2004; 9: 385–93
   PubMed Web of Science ®Google Scholar
• Moyle G, Sutinen J. Managing HIV lipoatrophy. Lancet 2004; 363: 412–4
   PubMed Web of Science ®Google Scholar
• Moyle GJ. The role of zidovudine in development of lipoatrophy. AIDS Read 2005; 15: 591–4–599–600, 603
   PubMedGoogle Scholar
• Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002; 46: 716–23
   PubMed Web of Science ®Google Scholar
• Martin A, Smith DE, Carr A, Ringland C, Amin J, Emery S, et al. Reversibility of lipoatrophy in HIV-infected patients 2 y after switching from a thymidine analogue to abacavir: the MITOX Extension Study. Aids 2004; 18: 1029–36
   PubMed Web of Science ®Google Scholar
• McComsey GA, Ward DJ, Hessenthaler SM, Sension MG, Shalit P, Lonergan JT, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 2004; 38: 263–70
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Sabin CA, Cartledge J, Johnson M, Wilkins E, Churchill D, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. Aids 2006; 20: 2043–50
   PubMed Web of Science ®Google Scholar
• Podzamczer D, Ferrer E, Sanchez P, Gatell JM, Crespo M, Fisac C, et al. Less lipoatrophy and better lipid profile with abacavir compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 2007; 44: 139–47
   PubMed Web of Science ®Google Scholar
• Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. Aids 2003; 17: 971–9
   PubMed Web of Science ®Google Scholar
• Connolly N, Manders E, Riddler S. Suction-assisted lipectomy for lipodystrophy. AIDS Res Hum Retroviruses 2004; 20: 813–5
   PubMed Web of Science ®Google Scholar
• Sax PE. Strategies for management and treatment of dyslipidaemia in HIV/AIDS. AIDS Care 2006; 1: 149–57
   Web of Science ®Google Scholar
• Mobius U, Lubach-Ruitman M, Castro-Frenzel B, Stoll M, Esser S, Voigt E, et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidaemia. J Acquir Immune Defic Syndr 2005; 39: 174–80
   PubMed Web of Science ®Google Scholar
• Noor MA, Flint OP, Maa JF, Parker RA. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. Aids 2006; 20: 1813–21
   PubMed Web of Science ®Google Scholar
• Jones R, Sawleshwarkar S, Michailidis C, Jackson A, Mandalia S, Stebbing J, et al. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone. HIV Med 2005; 6: 396–402
   PubMed Web of Science ®Google Scholar
• Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-y randomized trial. JAMA 2004; 292: 191–201
   PubMed Web of Science ®Google Scholar
• Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicentre AIDS cohort study. Arch Intern Med 2005; 165: 1179–84
   PubMed Web of Science ®Google Scholar
• Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993–2003
   PubMed Web of Science ®Google Scholar
• Keiser PH, Sension MG, DeJesus E, Rodriguez A, Olliffe JF, Williams VC, et al. Substituting abacavir for hyperlipidaemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virological suppression, and simplifies treatment. BMC Infect Dis 2005; 5: 2
   PubMed Web of Science ®Google Scholar
• Llibre JM, Domingo P, Palacios R, Santos J, Perez-Elias MJ, Sanchez-de la Rosa R, et al. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir. Aids 2006; 20: 1407–14
   PubMed Web of Science ®Google Scholar
• Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg JA, Blaschke T, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV-seronegative volunteers: ACTG Study A5047. Aids 2002; 16: 569–77
   PubMed Web of Science ®Google Scholar
• Hsyu PH, Schultz-Smith MD, Lillibridge JH, Lewis RH, Kerr BM. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 2001; 45: 3445–50
   PubMed Web of Science ®Google Scholar
• Prezista, SPC. Janssen-Cilag. 2007. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/prezista/H-707-PI-en.pdf
   Google Scholar
• Carr A. Lactic acidaemia in infection with human immunodeficiency virus. Clin Infect Dis 2003; 36(Suppl 2)S96–100
   PubMed Web of Science ®Google Scholar
• Arenas-Pinto A, Grant AD, Edwards S, Weller IV. Lactic acidosis in HIV-infected patients: a systematic review of published cases. Sex Transm Infect 2003; 79: 340–3
   PubMed Web of Science ®Google Scholar
• Geddes R, Knight S, Moosa MY, Reddi A, Uebel K, Sunpath H. A high incidence of nucleoside reverse transcriptase inhibitor (NRTI)-induced lactic acidosis in HIV-infected patients in a South African context. S Afr Med J 2006; 96: 722–4
   PubMed Web of Science ®Google Scholar
• Lonergan JT, Barber RE, Mathews WC. Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactataemia and lactic acidosis. Aids 2003; 17: 2495–9
   PubMed Web of Science ®Google Scholar
• Servoss JC, Kitch DW, Andersen JW, Reisler RB, Chung RT, Robbins GK. Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989–1999). J Acquir Immune Defic Syndr 2006; 43: 320–3
   PubMed Web of Science ®Google Scholar
• Nunez M, Soriano V. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Drug Saf 2005; 28: 53–66
   PubMed Web of Science ®Google Scholar
• Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006; 42: 283–90
   PubMed Web of Science ®Google Scholar
• Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005; 40: 1194–8
   PubMed Web of Science ®Google Scholar
• Winston A, Amin J, Mallon P, Marriott D, Carr A, Cooper DA, et al. Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Med 2006; 7: 105–11
   PubMed Web of Science ®Google Scholar
• Crixivan, SPC. Merck, Sharp and Dohme. 2007. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Crixivan/H-128-PI-en.pdf.
   Google Scholar
• Boyd MA, Siangphoe U, Ruxrungtham K, Reiss P, Mahanontharit A, Lange JM, et al. The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity. J Antimicrob Chemother 2006; 57: 1161–7
   PubMed Web of Science ®Google Scholar
• Dieleman JP, Gyssens IC, van der Ende ME, de Marie S, Burger DM. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. Aids 1999; 13: 473–8
   PubMed Web of Science ®Google Scholar
• Viramune, SPC. Boehringer Ingelheim. 2007. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Viramune/H-183-PI-en.pdf.
   Google Scholar
• Ziagen, SPC. Glaxo. 2007. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Ziagen/H-252-PI-en.pdf.
   Google Scholar
• Clay PG. The abacavir hypersensitivity reaction: a review. Clin Ther 2002; 24: 1502–14
   PubMed Web of Science ®Google Scholar
• Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359: 727–32
   PubMed Web of Science ®Google Scholar
• Martin AM, Nolan D, Gaudieri S, Almeida CA, Nolan R, James I, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci U S A 2004; 101: 4180–5
   PubMed Web of Science ®Google Scholar
• www.allelefrequencies.net. Accessed 2007-02-20.
   Google Scholar
• Center for Disease Control and Prevention. 1994. Revised classification system for HIV infection in children less than 13 y of age. MMWR Morbidity and mortality weekly report 1994;43:1–10.
   Google Scholar